When to Use Antimuscarinics in Men Who Have Lower Urinary Tract Symptoms

Urologic Clinics of North America

Volumn 33, Issue 4, 2006, Pages 531-537

  Lee, Ji Youl ^a   Kim, Dae Kyung ^b   Chancellor, Michael B ^c  

^a The Catholic University of Korea   (South Korea)

^b Eulji University School of Medicine   (South Korea)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DOXAZOSIN; FREE RADICAL; MESSENGER RNA; MUSCARINIC RECEPTOR BLOCKING AGENT; PROPIVERINE; PROSTATE SPECIFIC ANTIGEN; TOLTERODINE;

ACETYLCHOLINE RELEASE; BLADDER NECK STENOSIS; CLINICAL TRIAL; DETRUSOR MUSCLE; DIZZINESS; DRUG DOSE REGIMEN; EJACULATION DISORDER; EXPERIMENTAL RAT; HUMAN; MONOTHERAPY; NONHUMAN; ORTHOSTATIC HYPOTENSION; OVERACTIVE BLADDER; PALLIATIVE THERAPY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; REVIEW; SUSTAINED DRUG RELEASE; UNITED STATES; URGE INCONTINENCE; URINARY TRACT DISEASE; URINE RETENTION; URODYNAMICS; UROFLOWMETRY; XEROSTOMIA;

HUMANS; MALE; MUSCARINIC ANTAGONISTS; PROSTATISM; URINARY BLADDER NECK OBSTRUCTION;

EID: 33749021921     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ucl.2006.06.013     Document Type: Review

References (26)

1. Leppanen M.K. A cystometric study of the function of the urinary bladder in prostatic patients. Urol Int 14 (1962) 226-238
2. Price D.A., Ramsden P.D., and Stobbart D. The unstable bladder and prostatectomy. Br J Urol 52 6 (1980) 529-531
3. Brading A.F., and Turner W.H. The unstable bladder: towards a common mechanism. Br J Urol 73 1 (1994) 3-8
4. Blaivas J.G. Obstructive uropathy in the male. Urol Clin North Am 23 3 (1996) 373-384
5. Stewart W.F., Van Rooyen J.B., Cundiff G.W., et al. Prevalence and burden of overactive bladder in the United States. World J Urol 20 6 (2003) 327-336
6. Irwin D.E., Milsom I., Kopp Z., et al. Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries. BJU Int 97 1 (2006) 96-100
7. Andersen J.T. Detrusor hyperreflexia in benign inravesical obstruction. A cystometric study. J Urol 115 5 (1976) 532-534
8. Andersen J.T., Nordling J., and Walter S. Prostatism. I. The correlation between symptoms, cystometric and urodynamic findings. Scand J Urol Nephrol 13 3 (1979) 229-236
9. Geirsson G., Fall M., and Lindstrom S. Subtypes of overactive bladder in old age. Age Ageing 22 2 (1993) 125-131
10. Blaivas J.G. Pathophysiology and differential diagnosis of benign prostatic hypertrophy. Urology 32 6 Suppl (1988) 5-11
11. Speakman M.J., Brading A.F., Gilpin C.J., et al. Bladder outflow obstruction-a cause of denervation supersensitivity. J Urol 138 6 (1987) 1461-1466
12. Sutherland R.S., Baskin L.S., Kogan B.A., et al. Neuroanatomical changes in the rat bladder after bladder outlet obstruction. Br J Urol 82 6 (1998) 895-901
13. Brading A.F. A myogenic basis for the overactive bladder. Urology 50 6A Suppl (1997) 57-67 [discussion: 68-73]
14. Elbadawi A., Yalla S.V., and Resnick N.M. Structural basis of geriatric voiding dysfunction. III. Detrusor overactivity. J Urol 150 5 Pt 2 (1993) 1668-1680
15. Levin R.M., Levin S.S., Zhao Y., et al. Cellular and molecular aspects of bladder hypertrophy. Eur Urol 32 Suppl 1 (1997) 15-21
16. Andersson K.E., and Yoshida M. Antimuscarinics and the overactive detrusor-which is the main mechanism of action?. Eur Urol 43 1 (2003) 1-5
17. Andersson K. Alpha1-adrenoceptors and bladder function. Eur Urol 36 Suppl 1 (1999) 96-102
18. Yono M., Foster Jr. H.E., Shin D., et al. Doxazosin-induced up-regulation of alpha 1A-adrenoceptor mRNA in the rat lower urinary tract. Can J Physiol Pharmacol 82 10 (2004) 872-878
19. Lee J.Y., Kim H.W., Lee S.J., et al. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int 94 6 (2004) 817-820
20. Abrams P. Tolterodine therapy in men with bladder outlet obstruction and symptomatic detrusor overactivity is not associated with urinary safety concerns. J Urol 167 Suppl 2002 (2002) 1048
21. Abrams P., Kaplan S.A., and Millard R. Tolterodine treatment is safe in men with bladder outlet obstruction (BOO) and symptomatic detrusor overactivity (DO). Neurourol Urodyn 20 (2001) 547-548
22. Lee K.S., Choo M.S., Kim D.Y., et al. Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. J Urol 174 4 Pt 1 (2005) 1334-1338
23. Okada H., Shrakawa T., Muto S., et al. Propiverine hydrochloride relieves irritative symptoms of benign prostatic hyperplasia. J Urol Suppl 171 (2004) 357
24. Knutson T., Edlund C., Fall M., et al. BPH with coexisting overactive bladder dysfunction-an everyday urological dilemma. Neurourol Urodyn 20 3 (2001) 237-247
25. Athanasopoulos A., Gyftopoulos K., Giannitsas K., et al. Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol 169 6 (2003) 2253-2256
26. Kaplan S.A., Walmsley K., and Te A.E. Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol 174 6 (2005) 2273-2275 [discussion: 2275-76]